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Introduction. Recent studies have shown that acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) may serve as
important diagnostic and therapeutic targets in sepsis. Since polymorphonuclear neutrophils (PMNs) play a pivotal role in the
early phase of sepsis, we evaluated the potential therapeutic eﬀects of cholinesterase inhibitors on PMN functions during cecal
ligation and puncture- (CLP-) induced sepsis and investigated the roles of AChE and BChE as inﬂammatory markers under
standardized experimental conditions. Methods. Sham surgery or CLP was performed in male Wistar rats (n = 60). Animals
were randomized into four groups: physostigmine, 100μg/kg; neostigmine, 75 μg/kg; 0.9% saline (control group); and sham
group, each applied four times over 24 h. The levels of reactive oxygen species (ROS) production and CD11b/CD62l expression
were quantiﬁed by ﬂow cytometry at t = 0, 6, 15, 20, and 24 h. Blood gas analysis as well as AChE and BChE activity levels was
measured by validated point-of-care measurements. Clinical scores and survival times were determined. Results. CLP induced a
signiﬁcant increase in ROS production and CD11b upregulation by rat PMNs. Treatment with physostigmine or neostigmine
signiﬁcantly reduced ROS production and CD11b upregulation by PMNs 20 h after CLP induction. In physostigmine-treated
animals, survival times were signiﬁcantly improved compared to the control animals, but not in neostigmine-treated animals.
While AChE activity signiﬁcantly decreased in the control animals at t > 6 h, AChE activity did not change in the sham group.
BChE activity decreased at t > 20 h in the control animals. Conclusion. While AChE activity may serve as an acute inﬂammatory
marker, BChE activity shows a delayed decrease. Administration of centrally acting physostigmine in CLP-induced sepsis in rats
has protective eﬀects on PMN functions and improves survival times, which may be of interest in clinical practice.
1. Introduction
Sepsis and septic shock are major challenges in modern
intensive care. Treatment of the causative infection is funda-
mental for successful treatment of sepsis, but the course can
be positively inﬂuenced by supportive and adjuvant mea-
sures. The body’s ﬁrst defense against invading pathogens
or tissue injury is the innate immune system, which involves
a complex network of cytokines produced by activated
leukocytes. However, overproduction of these mediators
and their release into the bloodstream are characteristics of
the early phase of sepsis [1], resulting in secondary tissue
injury, organ dysfunction, and systemic inﬂammation with
potentially lethal multiorgan failure.
Polymorphonuclear neutrophils (PMNs) are multifunc-
tional cells that play a pivotal role in the inﬂammatory injury
of sepsis. PMN rolling and adherence on activated endothe-
lium are critical steps in transendothelial migration.
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L-selectin (CD62l) is an adhesion molecule on the surface of
PMNs that promotes rolling. Firm adherence and diapedesis
are mediated by Mac-1 (CD11b/CD18). Furthermore, the
generation of reactive oxygen species (ROS) by PMNs plays
an essential role in PMN-mediated host defense [2, 3]. Further
clariﬁcationof the role ofPMNsand therapeuticmanipulation
of PMN-mediated actions in sepsis is imperative.
Previous publications have indicated that the activation of
central cholinergic signalingand thecentral actionof cholines-
terase inhibitors activate the cholinergic anti-inﬂammatory
pathway (CAP) and alleviate systemic inﬂammation in
inﬂammatory bowel disease or murine endotoxemia [4–8].
Peter et al. showed in a model of experimental endotoxemia
that thenumberof rolling leukocyteswas signiﬁcantly reduced
by the application of physostigmine, a cholinesterase inhibitor
which crosses the blood-brain barrier [9]. Hofer and col-
leagues demonstrated that physostigmine as well as neostig-
mine, a cholinesterase inhibitor which only acts in the
periphery, improved survival in a murine cecal ligation and
puncture (CLP) model [10]. These data are quite diﬀerent
from those of the previous studies byAkinci et al., which failed
to demonstrate protective eﬀects of neostigmine in a murine
model of endotoxin-induced septic shock [11]. In addition,
Kox et al. reported no protective eﬀect of neostigmine on
ventilation-induced cytokine responses, lung injury, and func-
tion [12]. The cause for the variation in results between these
studies with centrally acting physostigmine and peripherally
acting neostigmine is still in focus of current research.
Recent studies have shown that acetylcholinesterase
(AChE) and butyrylcholinesterase (BChE) serve as diagnos-
tic markers of low-grade systemic inﬂammation [13–15].
Rapid changes in cholinesterase activity have also been
reported in patients after acute trauma, infections, burns,
and critical illness [16–20]. Both enzymes may serve as indi-
cators of systemic inﬂammation and have a remarkable pre-
dictive value for mortality in critically ill patients. However,
due to high variability in the onset, etiology, and progress
of clinical conditions among patients, determining whether
changes in the enzyme activity are correlated with the emer-
gence of disease or are aﬀected by other concomitant factors
is diﬃcult.
Since the role of AChE and BChE activity has not yet
been evaluated under standardized experimental conditions,
we investigated the changes in enzyme activity during
CLP-induced inﬂammatory responses. In this comparative
study, we further investigated the eﬀects of peripherally act-
ing neostigmine and centrally acting physostigmine on typi-
cal immune functions of PMNs, such as adhesion and ROS
generation, and examined the potential of cholinesterase
inhibitors for use in the early treatment of sepsis.
2. Materials and Methods
2.1. Animals. The animal experiments were conducted in
accordance with the German laws regulating animal care, the
European Communities Council Directive (2010/63/EU),
and institutional guidelines (Zentrale Tierlaboratorien, Uni-
versität Regensburg). All animal experiments were approved
by the Zentrale Tierlaboratorien, Universität Regensburg,
and the local ethics committee (Regierung der Oberpfalz,
Regensburg, Germany) under permit number 54-2532.1-21/12.
Rats were housed in a temperature-controlled room at
22 ± 0 5°C. Free access to food and water was allowed
throughout the experimental period. In total, 60maleWistar
rats (Charles River, Sulzfeld, Germany) weighing 250-350 g
each were included in the study. All eﬀorts weremade to pre-
vent animal suﬀering.
2.2. Study Design. Figure 1 describes the experimental pro-
tocol. A total of 60 rats were randomly allocated to 4
groups: (i) the control group, n = 18; (ii) the physostigmine
group, n = 14; (iii) the neostigmine group, n = 14; and (iv)
the sham group, n = 14. In detail, during a 20 to 25min time
period, a catheter was implanted in the vena jugularis interna
and CLP or sham operation procedures were performed
under anesthesia. At the end of surgery, physostigmine
(100μg/kg body weight; Dr. F. Köhler Chemie, Bensheim,
Germany), neostigmine (75μg/kg body weight; Rotexme-
dica, Trittau, Germany), or 0.9% saline was immediately
administered by intraperitoneal injection. The saline group
served as the control group. These animals received only
saline 0.9% in equivalent volumes. Administration of phy-
sostigmine, neostigmine, or saline 0.9% was repeated after
6, 15, and 20 h. Blood samples were drawn immediately, 6,
15, 20, and 24h after CLP/sham surgery and replaced by
0.6mL of saline solution. To investigate the therapeutic
eﬀects, neostigmine, physostigmine, or placebo was admin-
istered by intraperitoneal injection four times over 24 h.
The animals were evaluated regularly (clinical appearance
score, breathing rate). All surviving animals were eutha-
nized after 24 h by decapitation, and their organs were dis-
sected and isolated for histopathologic examination. Blood
was collected for biochemical analyses according to the
time points in Figure 1. No antibiotics were administered
in this model.
2.3. Anesthesia and Surgery. After intraperitoneal injection
of 150μg/kg of medetomidine, 2mg/kg of midazolam, and
5μg/kg of fentanyl, the sham operation (only laparotomy,
no ligation or puncture of the cecum) was carried out or
CLP was performed. CLP was performed as described in
detail in the previous work [21, 22]. The vena jugularis
interna was exposed and cannulated using a 26-gauge needle.
A 3Fr polyurethane catheter was inserted into the vein and
tunneled under the coat to the back of the animal to allow
easy blood sampling without stressing the animals or fur-
ther anesthesia.
2.4. Weight and Clinical Appearance Score. The animals’
weights were determined at t = 0, 6, 15, 20, and 24 h, using
a laboratory precision balance (BP 221 S, Sartorius, Göttin-
gen, Germany). A laboratory assistant blinded to the animals’
group assignments assessed and graded the clinical appear-
ance of the animals on a four-point scale ranging from 0 to
3. Three parameters were evaluated: eyes (0= open; 1=half
open; 2 = crusting exudate; and 3= closed, crusted, ensan-
guined), coat (0 =normal, shiny; 1 =dull; 2 = scrubby; and
3= very scrubby, crusted), and movement (0 = eat, move,
2 Mediators of Inﬂammation
drink, and keep themselves clean; 1 = less movement;
2 = lethargic, movement only by contact; and 3=no move-
ment, lack of pain) [23].
2.5. Blood Sampling
2.5.1. Blood Gas Analysis. Venous blood samples were col-
lected at the ﬁve time points indicated in Figure 1. pH,
pCO2, pO2, base excess, K
+, Na+, Ca2+, Cl−, Hb, CO-Hb,
Met-Hb, hematocrit, glucose, lactate, and SO2 were analyzed
by a blood gas analyzer (IL GEM 3000, Instrumentation
Laboratories, Kirchheim, Germany).
2.5.2. Oxidative Burst Assay and Immunostaining with
Anti-CD11b or Anti-CD62l
(1) Oxidative Burst Assay. The oxidative burst assay has been
performed as described previously [24, 25]. For quantifying
the oxidative burst, 2 × 10 μL heparinized whole blood was
collected at the ﬁve time points indicated in Figure 1. Both
samples for each time point were divided into two groups
(ROS sample group: without further in vitro stimulation
and n-formyl-methionyl-leucyl phenylalanine (fMLP) sam-
ple group: with further fMLP in vitro stimulation). Each
sample was suspended in 1mL PBS (Dulbecco’s without
Ca and Mg, PAA, Pasching, Austria) and loaded with
the ﬂuorogenic substrates dihydrorhodamine (DHR; 10μL,
100μM) and carboxy-seminaphthorhodaﬂuor-1-acetoxy-
methylester (SNARF/AM, 10μL, 10μM) (both purchased
from Molecular Probes, Eugene, OR, USA). Following incu-
bation for 10min at 37°C, 10μL, 1μM fMLP (Sigma-Aldrich,
Steinheim, Germany) was added to the fMLP sample group,
not to the ROS sample group. Finally, after further incuba-
tion (30min, 37°C), dead cells were counterstained with
10μL, 1.5μM propidium iodide (PI, Serva, Heidelberg, Ger-
many). Subsequently, the samples were placed on ice to stop
any further reaction.
(2) Immunostaining with Anti-CD11b or Anti-CD62l. For
immunostaining, 10μL heparinized whole blood was collected
at the ﬁve time points indicated in Figure 1. Samples were loaded
with a 10μL aliquot of ﬂuorescein isothiocyanate-conjugated
(FITC) anti-rat CD62l-speciﬁc monoclonal antibody (Beckman
Coulter GmbH, Krefeld, Germany) or a 10μL aliquot of
FITC anti-rat CD11b-speciﬁc monoclonal antibody (Bio-
Legend, San Diego, California, USA). After incubation
(30min), the samples were placed on ice.
(3) Red Blood Cell Lysis and Flow Cytometric Measurement of
Oxidative Burst and Adhesion Molecules. Afterwards, 2mL
(4°C) red blood cell lysis buﬀer (8.3 g/L ammonium chloride,
1.68 g/L sodium bicarbonate, and 0.358 g/L EDTA; all Merck,
Darmstadt, Germany) was added. Following 15min incuba-
tion in the dark (4°C), 2mL PBS was added to stop lysis. After
a ﬁnal washing step, the cells were dissolved in 200μL PBS.
For analysis, 5000 cells of each stained sample were
acquired at 488nm excitation (argon ion laser) using a
FACSCalibur™ ﬂow cytometer and the CellQuest Pro™ soft-
ware (Becton Dickinson, San José, California, USA). The cells
were analyzed immediately after preparation, and the tubes
were kept on ice during data collection.
The oxidative burst was measured by the indicator dye
DHR. The nonﬂuorescent DHR was oxidized intracellulary
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Figure 1: Illustration of the experimental proceeding. Animals were randomized into four groups: the sham, physostigmine, neostigmine,
and control groups. Neostigmine (75 μg/kg), physostigmine (100 μg/kg), and 0.9% saline (=control) were administered immediately, 6, 15,
and 20 h after CLP induction. Blood samples (BS) were drawn immediately, 6, 15, 20, and 24 h after CLP/sham procedures. The animals
were evaluated regularly (clinical appearance score, breathing rate). All surviving animals were euthanized after 24 h by decapitation, and
their organs were isolated for histopathologic examination.
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to green ﬂuorescent rhodamine 123. The amount of rho-
damine 123 was proportional to generated ROS. The dead
cells were identiﬁed by increased PI ﬂuorescence (emission
above 600nm) and lack of esterase activity determined based
on SNARF1-related orange ﬂuorescence. SNARF1/AM
(nonﬂuorescent) was cleaved in vital leukocytes by ester-
ases to SNARF1. FITC-labeled antibody produced ﬂuores-
cence, allowing the quantiﬁcation of expression of CD62l
or CD11b. PMNs were identiﬁed by their typical side
and forward scatter pattern and their SNARF-1 ﬂuores-
cence. Evaluation and measurement of each specimen have
been conducted in double measurement determination.
The results of cellular ﬂuorescence were expressed as mol-
ecules of equivalent soluble ﬂuorochrome (MESF).
2.5.3. Analysis of AChE and BChE Activity. For the AChE or
BChE activity analysis, 10μL of whole blood was collected at
the ﬁve time points indicated in Figure 1. We used ChE
Check (Securetec Detektions-Systeme AG, Neubiberg, Ger-
many; In Vitro Diagnostics Guideline 98/79/EG; DIN EN
ISO 18113-2 and -3), a validated point-of-care testing device,
to determine the AChE and BChE activities according to the
instructions from the manufacturer. This enzymatic assay
enables the rapid and precise determination of AChE and
BChE activities in whole blood without sample pretreatment.
The AChE and BChE activities were assayed at room tem-
perature using two separate test kits for each enzyme by
indirectly measuring the production of thiocholine from
the hydrolysis of their respective speciﬁc substrates, acet-
ylthiocholine iodide and s-butyrylthiocholine iodide. Thio-
choline further reacts with 5,5′-dithio-bis-2-nitrobenzoic
acid (DTNB, Ellman’s reagent) as a chromogenic reagent
to produce a yellow product, the 5-thio-2-nitrobenzoate
anion (TNB, Ellman’s anion). The production of TNB was
monitored at 470nm. Enzymatic activities were expressed
as U/L for BChE and as U/gHb for AChE according to the
manufacturer’s instructions [26].
2.6. Histopathologic Examination. The lungs, livers, kidneys,
and spleens of the animals were dissected from the surround-
ing tissue. Organs were prepared for blinded histopathologic
assessment. Tissues were ﬁxed in 4% neutral-buﬀered for-
malin for 48 h. After embedding in paraﬃn, the tissues
were sectioned with a microtome at 4μm and stained with
hematoxylin-eosin. The slides were examined under con-
ventional light microscopy (Leitz DM-RBE, Leica, Wetzlar,
Germany). A pathologist blinded to the study groups
assessed and scored the degree of tissue injuries using a scor-
ing system developed by Akinci et al. with a four-point scale
ranging from 0 to 3. The total organ injury score was calcu-
lated by adding all parameters for lungs, livers, kidneys, and
spleens (maximum score of 45) [11].
2.7. Statistical Analysis. G∗Power 3.1.3 software (University
Düsseldorf, Germany) was used to determine the sample size
(power 80%, signiﬁcance level alpha=5%). All data in the
text, tables, and ﬁgures are displayed as the means ± standar
d error of the mean (SEM) or standard deviation (SD). For
the statistical analysis, we applied the Kolmogorov-Smirnov
test to conﬁrm the normal distribution for each group. Statis-
tical signiﬁcance was tested using analysis of variance, Fried-
man’s two-way ANOVA, or the Kruskal-Wallis test. Post hoc
analysis was performed by using the Bonferroni comparison
test. p < 0 05 was considered statistically signiﬁcant. The sta-
tistical software used to conduct the analyses was SPSS 24
(SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Survival Time. Immediately after CLP induction, the rats
were treated with either physostigmine, neostigmine, or
saline four times over 24h. Physostigmine-treated animals
survived signiﬁcantly longer than the control rats receiving
the saline (mean survival time in hours, control: 17 5 ± 2 6
vs. physostigmine: 20 5 ± 2 3 (p < 0 05); control vs. neostig-
mine 18 3 ± 2 9 (n.s.), Figure 2).
3.2. Blood Gas Analysis, Clinical Score, and Weight. Table 1
shows the weights and the clinical appearance scores of the
animals at various treatment times. No signiﬁcant diﬀerence
in the breathing rates was observed between the groups dur-
ing the entire experiment (p = n s ). Body weight did not
change over time in any group (p = n s ).
The animals appeared healthy for approximately 10 h.
Then, the animals in the control and treatment groups
became subsequently ill and exhibited the typical behavior
and appearance described by Wichtermann et al. [23]. The
clinical appearance scores for eyes, coat, and movement were
signiﬁcantly higher in the placebo and treatment groups than
the sham group ($p < 0 05, Table 1). pCO2, pO2, K+, Na+,
Ca2+, Cl−, Hb, CO-Hb, Met-Hb, hematocrit, and SO2 did
not change signiﬁcantly during the entire experiment in
any group (p = n s , Table 2). The treated animals and the
control group showed increasing lactate levels during the
experiment, which reached signiﬁcance at t ≥ 20 h
(∗p < 0 05 versus t = 0, Table 2). In the control group, base
excess was signiﬁcantly reduced at t ≥ 20 h (∗p < 0 05 versus
t = 0, Table 2), but not in the treated animals or the sham
group. After 15 h, the pH and base excess of the sham group
were signiﬁcantly higher than those of the control and treat-
ment groups ($p < 0 05 versus control/treatment, Table 2).
Glucose levels signiﬁcantly decreased over time in all groups
(∗p < 0 05 versus t = 0). At t ≥ 15 h, glucose levels were signif-
icantly higher in the sham group than in the control and treat-
ment groups ($p < 0 05 versus the control/treatment group).
3.3. Production of Reactive Oxygen Species by PMN.
Figures 3(a) and 3(b) show that ROS production in the sham
group (n = 14) did not change signiﬁcantly during the entire
experiment. CLP-induced sepsis led to a strong increase in
ROS production, which showed signiﬁcance at t = 6, 15,
and 20h in the control (n = 18), physostigmine (n = 14),
and neostigmine (n = 14) groups (∗p < 0 05, Figure 3(a)). In
addition, the ROS production by PMNs following in vitro
stimulation with fMLP increased signiﬁcantly at t = 6, 15,
and 20h in the control group (∗p < 0 05, Figure 3(b)). In con-
trast, the animals treated with either physostigmine or neo-
stigmine showed signiﬁcantly decreased levels of ROS
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Table 1: Eﬀects of various treatments on the clinical appearance score, breathing rate, and body weights during the observation period
(results for physostigmine- and neostigmine-treated animals are combined as “treatment group”).
Clinical score Time (hours) Control (mean ± SD) Treatment (mean ± SD) Sham (mean ± SD)
Breathing rate (per min)
0 106 ± 7 6 n = 18 108 ± 11 8 n = 28 105 ± 19 3 n = 14
15 107 ± 19 6 n = 15 114 ± 13 7 n = 27 120 ± 11 4 n = 14
20 90 ± 22 3 n = 9 120 ± 17 3 n = 16 115 ± 18 0 n = 14
24 90 ± 14 1 n = 3 115 ± 26 6 n = 9 126 ± 12 8 n = 12
Coat (0-3)
0 0 ± 0 n = 18 0 ± 0 n = 28 0 ± 0 n = 14
15 2 2 ± 0 6∗ ,$ (n = 15) 2 2 ± 0 5∗ ,$ (n = 27) 0 45 ± 0 3 n = 14
20 2 5 ± 0 7∗ ,$ (n = 9) 2 7 ± 0 5∗ ,$ (n = 16) 0 36 ± 0 7 n = 14
24 3 0 ± 0 0∗ ,$ (n = 3) 2 7 ± 0 5∗ ,$ (n = 9) 0 29 ± 0 5 n = 12
Movement (0-3)
0 0 ± 0 n = 18 0 ± 0 n = 28 0 ± 0 n = 14
15 1 7 ± 0 6∗ ,$ (n = 15) 1 8 ± 0 6∗ ,$ (n = 27) 0 25 ± 0 3 n = 14
20 2 5 ± 0 5∗ ,$ (n = 9) 1 9 ± 0 8∗ ,$ (n = 16) 0 1 ± 0 3 n = 14
24 3 0 ± 0 0∗ ,$ (n = 3) 2 1 ± 0 7∗ ,$ (n = 9) 0 14 ± 0 4 n = 12
Eyes (0-3)
0 0 ± 0 n = 18 0 ± 0 n = 28 0 ± 0 n = 14
15 2 1 ± 0 3∗ ,$ (n = 15) 2 2 ± 0 6∗ ,$ (n = 27) 0 4 ± 0 7 n = 14
20 2 4 ± 0 5∗ ,$ (n = 9) 2 7 ± 0 5∗ ,$ (n = 16) 0 2 ± 0 4 n = 14
24 2 5 ± 0 7∗ ,$ (n = 3) 2 7 ± 0 5∗ ,$ (n = 9) 0 3 ± 0 5 n = 12
Weight (g)
0 250 ± 31 9 n = 18 265 ± 40 6 n = 28 248 ± 23 9 n = 14
15 247 ± 43 4 n = 15 256 ± 73 5 n = 27 256 ± 23 3 n = 14
20 264 ± 35 6 n = 9 262 ± 56 6 n = 16 259 ± 22 9 n = 14
24 246 ± 44 6 n = 3 282 ± 71 6 n = 9 270 ± 20 9 n = 12
There was no signiﬁcant diﬀerence of the breathing rates during the entire experiment in any group (p = n s ). The body weights did not change over time in any
group (p = n s ). The clinical appearance scores for eyes, coat, and movement were signiﬁcantly higher in the control and treatment group than in the sham
group ($p < 0 05 vs. the sham group). At t = 15 and 24 h, the clinical appearance score was in the placebo group and treatment groups signiﬁcantly higher
than at t = 0 (∗p < 0 05 vs. t = 0). The data are displayed as the means ± standard deviation (SD). ∗p < 0 05 versus t = 0. $p < 0 05 versus the sham group.
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Figure 2: Illustration of the mean survival times of the animals in the four groups. Immediately after CLP induction, the rats were treated with
either physostigmine, neostigmine, or saline four times over 24 h. While physostigmine-treated animals survived signiﬁcantly longer than the
control rats receiving the saline, the mean survival time of neostigmine-treated animals was not signiﬁcantly longer (mean survival time in
hours, control (n = 18): 17 5 ± 2 6 vs. physostigmine (n = 14): 20 5 ± 2 3 (§p < 0 05); control vs. neostigmine (n = 14): 18 3 ± 2 9 (p = n s )).
Box plots in panels represent medians with 25% and 75% percentiles; error bars are minimum and maximum values, Kruskal-Wallis test
followed by Bonferroni’s pairwise comparison test.
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production at t = 20 h compared to those in the control group
(§p < 0 05). The comparison between animals treated with
physostigmine or neostigmine showed no signiﬁcant diﬀer-
ences in ROS production over the whole course of the exper-
iment (p = n s ).
3.4. Expression of CD11b and CD62l on the Surface of PMNs.
In the sham group, CD62l was signiﬁcantly higher 6 h after
beginning the experiment (Figure 4(a)). In the control and
treatment groups, no signiﬁcant diﬀerences were observed
in CD62l expression over the whole course of the experiment.
CD11b expression in the sham group did not change sig-
niﬁcantly during the entire experiment (p = n s , Figure 4(b)).
CLP-induced sepsis led to a strong increase in CD11b expres-
sion, which showed signiﬁcance at t = 6 and 15-20 h in the
control group (∗p < 0 05). In the physostigmine and neo-
stigmine groups, CD11b expression increased, showing sig-
niﬁcance at t = 6 h (∗p < 0 05). At t = 15-20 h, CD11b
expression was signiﬁcantly reduced in the animals treated
with physostigmine or neostigmine compared with the
control group (§p < 0 05).
3.5. Histopathologic Examination. Histological examination
of the organs of the sham group showed a median histo-
logical injury score of 7 7 ± 2 5. The control group showed
increased organ injury in the lungs, livers, kidneys, and
spleens with a median histological injury score of 14 0 ±
2 7 (p < 0 05 vs. the control group). Neostigmine-treated
animals showed a median histological score of 11 3 ± 1 3,
and physostigmine-treated animals showed a median score
of 12 7 ± 3 6 (p = n s vs. the control group). Examples of
histopathologic images of rat lungs are shown in
Figures 5(a)–5(c).
3.6. Relative AChE and Relative BChE Activity during CLP.
Figures 6(a) and 6(b) show the relative AChE and relative
BChE activities over time. The relative activity at a given time
point was calculated as the ratio between the measured abso-
lute enzyme activity at the given time point and the enzyme
activity at t = 0. In the control group, AChE activity
decreased compared to that at baseline, showing signiﬁcance
at t = 6, 15, 20, and 24 h. In the sham group, no diﬀerences in
AChE activity were observed throughout the observation
period of 24 h. In the treatment group, AChE activity signif-
icantly decreased at t = 20 and 24h (Figure 6(a)). No signiﬁ-
cant diﬀerences in BChE activity were observed until t = 20 h
in any group. At t = 24 h, we observed a decreased BChE
activity in the control group (Figure 6(b)).
4. Discussion
The primary objective of the present investigation was to
evaluate the potential therapeutic eﬀects of cholinesterase
inhibitors on PMN functions during the early phase of sepsis
and to investigate the roles of AChE and BChE as inﬂamma-
tory markers in CLP-induced sepsis.
4.1. PMN Functions during CLP-Induced Sepsis. CLP causes
lethal peritonitis by polymicrobial infection and has been
identiﬁed as a relevant animal model for human sepsis [1].
Table 2: Results of blood gas analysis during the observation period of 24 h (results for physostigmine- and neostigmine-treated animals are
combined as “treatment group”).
Blood gas analysis Time (h) Control (mean ± SD) Treatment (mean ± SD) Sham (mean ± SD)
pH
0 7 37 ± 0 03 n = 18 7 37 ± 0 03 n = 28 7 37 ± 0 04 n = 14
15 7 46 ± 0 07∗ (n = 15) 7 47 ± 0 05∗ (n = 27) 7 52 ± 0 02§,∗ (n = 14)
20 7 37 ± 0 09 (n = 9) 7 44 ± 0 12 (n = 13) 7 48 ± 0 07 (n = 10)
24 7 35 ± 0 11 (n = 3) 7 41 ± 0 15 (n = 9) 7 46 ± 0 09§ (n = 12)
Base excess (mmol/L)
0 2 9 ± 1 38 (n = 18) 2 74 ± 1 64 (n = 28) 2 65 ± 1 64 (n = 14)
15 3 0 ± 3 58 (n = 15) 2 91 ± 4 30 (n = 27) 8 59 ± 5 39§ (n = 14)
20 -0 23 ± 5 46 (n = 9) 2 22 ± 7 32 (n = 13) 7 19 ± 4 89§ (n = 10)
24 -2 66 ± 6 66∗ (n = 3) -0 69 ± 9 19 (n = 9) 6 38 ± 5 16§ (n = 12)
Lactate (mmol/L)
0 1 36 ± 0 41 (n = 18) 1 37 ± 0 41 (n = 28) 1 28 ± 0 29 (n = 14)
15 1 64 ± 0 54 (n = 15) 1 32 ± 0 50 (n = 27) 1 36 ± 0 49 (n = 14)
20 6 59 ± 2 43∗ (n = 9) 4 66 ± 2 82∗ (n = 13) 1 47 ± 0 39 (n = 10)
24 6 78 ± 3 67∗ (n = 2) 5 35 ± 4 61∗ (n = 19) 1 70 ± 1 11§ (n = 12)
Glucose (mg/dL)
0 326 68 ± 86 16 (n = 18) 325 7 ± 69 54 (n = 28) 352 50 ± 30 06 (n = 14)
15 90 78 ± 13 41∗ (n = 15) 91 95 ± 21 84∗ (n = 27) 134 57 ± 11 70§,∗ (n = 14)
20 41 75 ± 23 28∗ (n = 9) 68 66 ± 29 37∗ (n = 13) 148 45 ± 17 80§,∗ (n = 10)
24 29 92 ± 34 38∗ (n = 2) 65 56 ± 47 27∗ (n = 9) 142 18 ± 32 15§,∗ (n = 12)
pCO2, pO2, K
+, Na+, Ca2+, Cl−, Hb, CO-Hb, Met-Hb, hematocrit, and SO2 did not change signiﬁcantly during the entire experiment in any group (data not
shown). The treated animals and the control group showed an increase of lactate levels over time, being signiﬁcant at t ≥ 20 h (∗p < 0 05 versus t = 0). In the
control group, base excess was signiﬁcantly reduced at t ≥ 20 h (∗p < 0 05 versus t = 0), but not in the treated animals or the sham group. After 15 h, pH and
base excess of the sham group were signiﬁcantly higher than in the control and treatment groups (§p < 0 05 versus placebo/treatment). Glucose levels
signiﬁcantly decreased over time in all groups (∗p < 0 05 versus t = 0). At t ≥ 15 h, glucose levels were signiﬁcantly higher in the sham group than in the
control and treatment groups (§p < 0 05 versus control/treatment). The data are presented as themean ± SD. ∗p < 0 05 versus t = 0; $p < 0 05 versus the control.
6 Mediators of Inﬂammation
CLP in rats causes an early septic period with hyperdynamic
circulation and hyperglycemia, while the late septic period
shows low levels of serum glucose and high levels of serum
lactate [14]. These observations were reproduced in the pres-
ent study (Table 2). Following CLP, most rats followed a pre-
dictable pattern of behavior and appearance, which was
previously described by Wichterman et al. [23]. Initially,
the rats rapidly recovered from anesthesia and generally
appeared healthy for approximately 10 h. The animals in
control and treatment groups became subsequently ill and
showed higher clinical appearance scores compared to the
animals in the sham group (Table 1).
The present results clearly demonstrate a signiﬁcant,
time-dependent increase in ROS production by PMNs after
CLP induction (Figures 3(a) and 3(b)). ROS production
peaked at t = 15 h and then decreased until t = 24 h. The
course of ROS production indicates an early, hyperinﬂam-
matory and a late, hypoinﬂammatory phase of sepsis. In the
literature, CLP has been shown to activate the peripheral
innate immune system, leading to the release of many
inﬂammatory mediators such as ROS [1]. Our results further
show a signiﬁcant downregulation of CD62l expression in
septic animals compared to the sham group, which is consis-
tent with the previous studies. Thiel et al. showed that in
critically ill patients with septic shock, the level of L-selectin
expression was decreased in circulating PMNs [27]. The
present results demonstrate a signiﬁcant upregulation of
CD11b expression on the PMN surface in the control ani-
mals. Increased expression of CD11b is part of the systemic
inﬂammatory response syndrome during the early phase of
sepsis [28]. Leukocyte recruitment is critical for the eﬀective
elimination of invading pathogens. However, excessive leu-
kocyte accumulation during inﬂammation mediated by the
overexpression of adhesion molecules can lead to tissue dam-
age. In contrast, insuﬃcient cell activation and subsequent
impaired immune cell traﬃcking can result in host immuno-
deﬁciency [9]. In the present study, CLP-induced sepsis
increased interstitial inﬂammation and histopathological
organ injury in general terms. While the organs of the sham
group showed a median histological injury score of 7 7 ± 2 5,
the control group showed signiﬁcantly increased organ
injury with a median histological injury score of 14 0 ± 2 7
(maximum score of 45). Therefore, the regulation of leuko-
cyte recruitment must be controlled precisely since it plays
a pivotal role in the clinical development and manifestation
of sepsis or septic shock. Further clariﬁcation of the role of
cholinesterase inhibitors in the therapeutic manipulation of
PMN actions in the early phase of sepsis is imperative.
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Figures 3: (a, b) Eﬀects of physostigmine and neostigmine treatment on ROS production of PMNs during CLP-induced sepsis in rats. (a)
ROS production in the sham group (n = 14) did not change signiﬁcantly during the entire experiment (p = n s ). In the control (n = 18),
physostigmine (n = 14) and neostigmine (n = 14) groups’ ROS production increased signiﬁcantly at t = 6, 15, and 20 h, respectively
(∗p < 0 05). (b) ROS production by PMNs following in vitro stimulation with fMLP increased signiﬁcantly at t = 6, 15, and 20 h in the
control group (∗p < 0 05). The animals treated with either physostigmine or neostigmine showed decreased levels of ROS production,
which reached signiﬁcance at t = 20 h (§p < 0 05). The comparison between the animals treated with either physostigmine or neostigmine
revealed no signiﬁcant diﬀerences in ROS production over the course of the experiment. The data are presented as the mean ± SEM.
∗p < 0 05 versus t = 0; §p < 0 05 versus the control, analysis of variance followed by Bonferroni’s multiple comparisons test.
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4.2. Eﬀects of Neostigmine or Physostigmine Treatment on
PMN Functions. The aim of the present study was to investi-
gate the eﬀects of peripherally and centrally acting cholines-
terase inhibitors on PMN functions during CLP-induced
sepsis in rats. Previous studies have shown that the CAP
can be pharmacologically activated by cholinesterase inhibi-
tors since elevated levels of acetylcholine inhibit the synthesis
of proinﬂammatory cytokines [5–8, 29]. However, no data
are available regarding the in vivo eﬀects of the CAP on
PMN functions during the early phase of sepsis. Compared
to Hofer et al., we did not use ketamine as an anesthetic for
CLP induction and avoided further anesthetics for blood
sampling during the experiment to mitigate potential phar-
macologic side eﬀects. Ketamine is a noncompetitive inhibi-
tor of the nicotinic acetylcholine receptor that may cause
the receptor to be unresponsive to acetylcholine elevations
induced by cholinesterase inhibitors [10].
Immediately after CLP induction, rats were treated with
either physostigmine, neostigmine, or saline four times over
24 h. Physostigmine and neostigmine are the two main cho-
linesterase inhibitors available in clinical practice, which are
used in the treatment of colonic ileus and central anticholin-
ergic syndrome or as an adjuvant in pain treatment [30, 31].
One diﬀerence between neostigmine and physostigmine is
the site of action. We compared treatment with physostig-
mine, which is lipid-soluble and crosses the blood-brain bar-
rier, to treatment with neostigmine, which only acts in the
periphery [12, 25].
The results of the present study demonstrate that physo-
stigmine and neostigmine have protective eﬀects on PMN
functions during CLP-induced sepsis. We found a signiﬁcant
reduction in ROS production by treatment with physostig-
mine as well as neostigmine. ROS production plays a central
role in modulating mortality in experimental and clinical
sepsis, and residual levels of ROS are probably necessary for
the clearance of bacterial infections. The observed downreg-
ulation of ROS production upon cholinesterase inhibition
in the early phase of sepsis seems to be important in the fur-
ther course of sepsis and is potentially an underlying reason
for the improved outcomes among the treated animals,
which showed less lactate acidosis and extended survival
times (Figure 2).
Furthermore, thepresent study demonstrated a signiﬁcant
inhibitory eﬀect of physostigmine or neostigmine on the
expression of CD11b on the surface of PMNs. Peter et al.
showed that the number of rolling leukocytes as well as
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Figures 4: (a, b) Eﬀects of physostigmine and neostigmine treatment on CD11b and CD62l expression levels of PMNs during CLP-induced
sepsis in rats. (a) In the sham group (n = 14), CD62l expression was signiﬁcantly higher 6 h after beginning the experiment (∗p < 0 05). In the
control (n = 18) and treatment groups (n = 14 neostigmine, n = 14 physostigmine), no signiﬁcant diﬀerences in CD62l expression were
observed over the course of the experiment. (b) CD11b expression in the sham group (n = 14) did not change signiﬁcantly during the
entire experiment (p = n s ). CLP-induced sepsis led to a strong increase in CD11b expression, which reached signiﬁcance at t = 6 and
15-20 h in the control group (n = 18, ∗p < 0 05). In the physostigmine (n = 14) and neostigmine (n = 14) groups, CD11b expression
increased, reaching signiﬁcance at t = 6 h. At t = 15-20 h, CD11b expression was signiﬁcantly reduced in the animals treated with
physostigmine or neostigmine compared with the control group (§p < 0 05). The data are presented as the mean ± SEM. ∗p < 0 05 versus
t = 0; §p < 0 05 versus the control, Friedman’s two-way ANOVA and Kruskal-Wallis test followed by Bonferroni’s pairwise comparison test.
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leukocyte-endothelial interactions was signiﬁcantly reduced
by the application of physostigmine during experimental
endotoxemia [9]. On the basis of these observations, the
reduced leukocyte-endothelial interactions seemed to be due
to reduced activation of adhesion molecules. Histopathologic
examination of tissue injury after 24 h observation time
showed reduced injury scores by trend in physostigmine-
andneostigmine-treated animals,whichwerenot signiﬁcantly
diﬀerent from that of the control group.
Administration of physostigmine or neostigmine reduced
ROSproduction andCD11bupregulation in the early phase of
sepsis, which was probably attributable to the peripheral
eﬀects of acetylcholine on the alpha7-nicotinic acetylcholine
receptor expressed on PMNs. This gives rise to the hypothesis
that the CAPmodulates the inﬂammatory functions of PMNs
and their respective interactions by integrating independent
cell-speciﬁc pathways [9].
The animals treated with physostigmine showed signiﬁ-
cantly improved survival times compared with those of the
control animals. In neostigmine-treated animals, in contrast,
survival times were not signiﬁcantly improved. Therefore,
peripheral stimulation of cholinergic receptors is suﬃcient
to confer protective eﬀects on PMN functions, but for
improved survival times during the early phase of sepsis the
additional lipid-soluble component of physostigmine seems
to be required.
These ﬁndings are consistent with those of the previous
study by Kox et al. [12], who reported no protective eﬀects
of neostigmine on ventilation-induced lung injury. Akinci
et al. investigated the eﬀects of neostigmine on organ injury
in mice during endotoxemia and failed to demonstrate pro-
tective eﬀects of neostigmine [11]. The authors suspected that
the reason for the higher mortality rates was the clinically
important cardiovascular side eﬀects of neostigmine, such
as bradycardia. We used neostigmine in a dose of 75μg/kg
and physostigmine in a dose of 100μg/kg, which are both
comparable with the doses used in the literature [10, 12, 32].
Interestingly, Hofer et al. showed improved survival in
murine CLP-induced sepsis after the application of neostig-
mine as well as physostigmine [10]. One main diﬀerence is
the varying times of observation. Since the focus of the pres-
ent study was on the early phase of sepsis, our observation
time stopped after 24 hours. In contrast, Hofer et al. observed
the animals for seven days. The integrity of the blood-brain
barrier may be compromised during sepsis and by drugs,
including neostigmine, whose action is peripherally restricted
(a) Rat lung sham group (b) Rat lung control group
(c) Rat lung treatment group
Figure 5: (a, b, and c) Histopathologic images of rat lungs. CLP induced an increase in organ injury in all examined tissues (median
histological injury score in the control group 14 0 ± 2 7 vs. the sham group 7 7 ± 2 5, p < 0 05, Kruskal-Wallis test followed by Bonferroni’s
pairwise comparison test). The median histological score of neostigmine-treated or physostigmine-treated animals was not signiﬁcantly
diﬀerent compared to the control group animals (p = n s vs. the control group). We present examples of histopathologic images of rat
lungs, since the diﬀerences between the groups are most apparent compared to other examined tissues: (a) Rat lung of the sham group
with little to no blood stasis and small vessel lumina. No signs of perivascular or interstitial inﬂammation, lung injury score 1. (b) Rat lung
of the control group with marked alveolar hemorrhage, congestion, and dilated, hyperemic blood vessels. PMN inﬁltrates lead to a strong
perivascular and interstitial inﬂammation, lung injury score 7. (c) Rat lung of an animal treated with physostigmine with intra-alveolar
edema and congestion. Only mild PMN inﬁltrates and little alveolar hemorrhage, lung injury score 4.
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under normal conditions may reach the brain and act cen-
trally. This is in accordance with our present ﬁndings that
some protective eﬀects on PMN functions are obtained at the
later 20 h time point, when treatment with neostigmine may
theoretically aﬀect the brain.
4.3. The Role of AChE and BChE as Inﬂammatory Markers in
CLP. Recent studies have shown that AChE and BChE serve
as diagnostic markers of low-grade systemic inﬂammation
[13–15]. Rapid changes in cholinesterase activity have also
been reported in patients after acute trauma, infections,
burns, and critical illness [16–20]. However, due to high var-
iability in the onset, etiology, and progress of clinical condi-
tions, it was diﬃcult to determine whether the change in
the enzyme activity correlated with the emergence of disease
or is aﬀected by concomitant factors such as substance abuse,
liver disease, or nephrotic disease [19]. This is the ﬁrst study
to investigate the roles of AChE and BChE as inﬂammatory
markers under standardized experimental conditions.
The ﬁndings of our study show that CLP-induced sepsis
caused a signiﬁcant and time-dependent decline in AChE
activity (Figure 6(a)). In the control group, AChE activity
decreased compared to that at baseline, showing signiﬁcance
at t = 6, 15, 20, and 24 h. At t = 24 h, AChE activity was sig-
niﬁcantly reduced by approximately 19%. Decreased AChE
activity can be associated with elevated proinﬂammatory
markers (ROS production, CD11b expression) in the circula-
tion during CLP-induced sepsis. Therefore, the AChE
decrease observed in our study is likely related to the patho-
physiological response to CLP, although the underlying
mechanism remains unclear. In a study on burn patients,
the decrease in cholinesterase activity has been suggested to
have multifactorial causes, such as decreased liver synthe-
sis, capillary leakage, or high enzyme consumption due
to stress-induced catabolic metabolism [20]. The decrease
in AChE activity correlated with the development of a lac-
tate acidosis, a conventional indicator of poor outcomes in
sepsis. Compared to lactate acidosis or other conventional
laboratory tests that are used to diagnose inﬂammation
[18, 33, 34], AChE activity changes can be detected much
earlier (at t = 6 h). Therefore, AChE may play an impor-
tant role in identifying early systemic inﬂammation.
In the treated animals, AChE activity also decreased com-
pared to that at baseline, showing signiﬁcance at t = 20 and
24 h. The delayed decrease in AChE activity in the treated
animals compared to that in the control group could be
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Figures 6: (a, b) Relative AChE and relative BChE activity during CLP-induced sepsis in rats (results for physostigmine- and
neostigmine-treated animals are combined as “treatment group”). Relative activity for the given time point was calculated as the ratio
between the measured absolute enzyme activity for the given time point and the enzyme activity at t = 0. (a) In the control group (n = 18),
AChE activity decreased versus baseline, being signiﬁcant at t = 6, 15, 20, and 24 h (∗p < 0 05). The sham group (n = 14) did not show any
diﬀerences in AChE activity during the observation time of 24 h. In the treatment groups (physostigmine and neostigmine, n = 28), AChE
activity signiﬁcantly decreased at t = 20 and 24 h (§p < 0 05). (b) There were no signiﬁcant diﬀerences of BChE activity until t = 20 h in any
group. At t = 24 h, BChE activity was signiﬁcantly decreased in the control group (n = 18, ∗p < 0 05). Box plots in panels represent
medians with 25% and 75% percentiles; error bars are minimum and maximum values. ∗p < 0 05 versus t = 0 in the placebo group.
§p < 0 05 versus t = 0 in the treatment group, Friedman’s two-way ANOVA followed by Bonferroni’s pairwise comparison test.
10 Mediators of Inﬂammation
associated with the positively inﬂuenced course of sepsis in
the treated animals. Therefore, AChE activity may also
play an important role in estimating the severity of inﬂam-
matory diseases.
In contrast, BChE activity did not change in any group
until t = 20 h (Figure 6(b)). At t = 24 h, we observed reduced
activity in the control group, but not in the treatment or sham
groups. The necessity and precise physiological function of
BChE remain largely unknown [16, 26]. BChE is synthesized
in the liver [17] and has therefore been conventionally used as
a liver function biomarker. Indeed, the work of al-Kassab and
Vijayakumar suggested the importance of BChE as an indica-
tor of hepatic dysfunction in septic syndrome [14]. In the
present study, we showed a decrease in BChE activity at
24 h, which could be associated with hepatic dysfunction in
septic rats. This is in accordance with the observed hypogly-
cemia in septic animals (Table 2) compared to the sham
group, which may also be a sign of hepatic dysfunction.
The CLP model used in this study has been shown to be a
suitable model for evaluating AChE and BChE as inﬂamma-
tory markers under standardized experimental conditions.
Our data indicate that BChE activity can be regarded as a
marker with delayed decrease, while AChE activity is an
acute marker and may serve as an early indicator of acute sys-
temic inﬂammation [35].
5. Limitations
The animals were not monitored hemodynamically in our
study, since we wanted to avoid additional manipulation of
the animals or any further anesthesia.
Further inﬂammatory biomarker analyses (e.g., CRP and
IL-6), which would require additional blood samples in small
animals, were not included.
6. Conclusion
While AChE activity could serve as an acute marker of sys-
temic inﬂammation in CLP-induced sepsis, BChE activity
shows a delayed decrease, which is consistent with the previ-
ous studies that demonstrated the remarkable predictive
value of cholinesterases for mortality in critically ill patient
populations. Our results suggest that the administration of
physostigmine or neostigmine after CLP induction in rats
leads to a signiﬁcant reduction in ROS production and
CD11b upregulation during the early phase of sepsis. Cen-
trally acting physostigmine, but not peripherally acting
neostigmine, improved survival times signiﬁcantly. These
ﬁndings provide a rationale for further exploration and
may be of interest in clinical practice. Anticholium® per Se,
for example, is a currently ongoing placebo-controlled trial
[36] exploring the adjunctive use of physostigmine in
patients with perioperative sepsis and septic shock.
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